Exicure, Inc. (XCUR) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Exicure, Inc. is a smaller reporting company that historically focused on nucleic acid therapies but suspended its original R&D in 2022 to explore strategic alternatives. In January 2025, the Company pivoted by acquiring GPCR Therapeutics USA Inc. (GPCR USA), a subsidiary focused on a Phase 2 clinical trial for blood cancer (Multiple Myeloma) using the GPC-100 compound. The Company also formed a South Korean subsidiary, KC Creation, in March 2025 to explore renewable energy and entertainment content opportunities.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $500,000 |
| Net Income (Loss) | $(2,621,000) | $389,000 | $(1,429,000) |
| Operating Expenses | $2,509,000 | $(414,000)* | $2,571,000 |
| Cash and Equivalents | $7,858,000 | $7,858,000 | $1,400,000 |
| Total Assets | $18,738,000 | $18,738,000 | $15,056,000 |
| Total Liabilities | $9,875,000 | $9,875,000 | $8,284,000 |
| Stockholders' Equity | $8,863,000 | $8,863,000 | $6,772,000 |
*YTD 2025 Operating Expenses include a $5.974 million gain on early lease termination, resulting in a net operating income for the six-month period.
Material Changes vs. Prior Period
- Acquisition Impact: The acquisition of GPCR USA in Q1 2025 introduced significant R&D expenses ($1.743 million YTD 2025 vs. $0 in 2024) and increased General and Administrative (G&A) expenses ($3.731 million YTD 2025 vs. $2.571 million in 2024).
- Lease Termination Gain: A non-recurring gain of $5.974 million was recognized in Q1 2025 due to the early termination of the Chicago lease, which significantly improved the YTD operating result compared to the prior year.
- Contingent Consideration: The Company recorded a liability of $5.306 million for contingent consideration related to the GPCR USA acquisition. A change in fair value resulted in a $295,000 loss for the six months ended June 30, 2025.
- Cash Position: Cash decreased by $4.65 million during the six months ended June 30, 2025, driven by operating cash outflows of $3.88 million and investing outflows of $2.37 million (primarily the GPCR USA acquisition).
Outlook, Risks, and Management Commentary
- Going Concern: Management has expressed substantial doubt about the Company's ability to continue as a going concern for the next 12 months. Current cash of $7.9 million is deemed insufficient to fund operations, and additional financing is required.
- Clinical Trial Status: GPCR USA completed administration of GPC-100 to 20 patients in Q2 2025. Results are expected to be announced in Q4 2025.
- Legal Proceedings: A securities class action settlement of $5.625 million was approved in January 2025. While covered by insurance, the Company is liable for a $2.5 million self-insured retainer; $1.0 million was remitted in July 2025 to satisfy the remaining obligation. Derivative lawsuits remain stayed but are in settlement discussions.
- Nasdaq Compliance: The Company received a delinquency notice in May 2025 for failing to file its Q1 10-Q on time but regained compliance upon filing on June 27, 2025.
- Internal Controls: Management identified a material weakness in internal controls over financial reporting related to the review of non-routine activities and lack of IT controls.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline and certainty of raising additional capital, as the Company explicitly states it may need to seek bankruptcy protection or cease operations if funding is not secured.
- Contingent Liability: Review the assumptions used to value the $5.541 million contingent consideration liability, as changes in probability of success for GPCR USA milestones will directly impact future earnings.
- Legal Retainer: Confirm the full satisfaction of the $2.5 million self-insured retainer obligation related to the class action settlement.
- Clinical Data: Monitor the Q4 2025 announcement of the GPC-100 Phase 2 trial results, which is critical to the valuation of the GPCR USA acquisition.
- Stock Split Adjustments: Ensure all share counts and per-share data are reviewed in the context of the 1-for-5 reverse stock split effected in August 2024.